Virax Biolabs Entered Agreement With H.C. Wainwright For $1.45M At The Market Share Offering
Virax Biolabs Entered Agreement With H.C. Wainwright For $1.45M At The Market Share Offering
On January 22, 2024, Virax Biolabs Group Limited, a Cayman Islands exempted company (the "Company"), entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC (the "Sales Agent"), acting as the Company's sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, its ordinary shares, par value $0.001 per share (the "Ordinary Shares"), having an aggregate offering amount of up to $1,455,029. On January 22, 2024, pursuant to the Sales Agreement, the Company filed a prospectus supplement, including an accompanying base prospectus, dated December 15, 2023, forming a part of its effective registration statement on Form F-3 (File No. 333-275893), initially filed with the Securities and Exchange Commission on December 5, 2023.
2024年1月22日，开曼群岛豁免公司（“公司”）Virax Biolabs Group Limited与担任公司销售代理的H.C. Wainwright & Co., LLC（“销售代理”）签订了市场发行协议（“销售协议”），根据该协议，公司可以不时通过销售代理发行和出售其普通股、面值每股价值0.001美元（“普通股”），总发行金额最高为1,455,029美元。2024年1月22日，根据销售协议，公司于2023年12月15日提交了招股说明书补充文件，包括随附的基本招股说明书，构成其在F-3表格（文件编号333-275893）上的有效注册声明的一部分，该声明最初于2023年12月5日向美国证券交易委员会提交。